A wise acquisition technique has made Bristol-Meyers, which has purchased seven firms since October 2007, a giant participant within the cancer-treatment business. Its buy of Medarex in July added a key drug for metastic melanoma that’s in Section III trials. The drug has attainable a number of indications – business jargon for its capacity to deal with a couple of situation – for lung and prostate most cancers.However BMY additionally sells Erbitux for colorectal, head and neck most cancers, Ixempra for breast most cancers, Taxol for brea
U.Ok. pharmaceutical large AstraZeneca is contemplating a deal to merge with its U.S. competitor Bristol Myers Squibb, in a deal that may worth the joint firm at roughly $400 billion, the Monetary Occasions reported on Sunday.
It is nonetheless unclear whether or not the deal will come collectively, however the firms have been discussing a merger over the previous few months, sources informed the FT.
The merger could be one of many largest in historical past.
AstraZeneca and Bristol Myers Squibb didn’t instantly reply to a CNBC request for remark.
Final yr, AstraZeneca unveiled plans for a direct U.S. itemizing, aiming to capitalize on stronger valuations within the U.S. market whereas remaining listed in London.
The corporate’s share worth has greater than quadrupled throughout Pascal Soriot’s 14-year tenure as CEO, hovering above the broader FTSE 100 index and predominant British rival GSK.
AstraZeneca’s second-quarter outcomes, posted final week, confirmed sturdy demand for most cancers and uncommon illness medicine continues to drive progress. Most cancers therapies accounted for about $25 billion in 2025 gross sales, almost half of the entire, adopted by cardiovascular, renal and metabolism therapies price about $12 billion.
The report of the potential deal comes about 12 years after AstraZeneca fended off a takeover bid from bigger U.S. rival Pfizer.
Learn the whole Monetary Occasions story right here.
— Reuters contributed to this report.
WATCH: AstraZeneca CFO: Very assured we’ll hit $80 billion income goal
